Notifications Bell

Johnson & Johnson plans to split

Johnson & Johnson plans to split

Healthcare giant Johnson & Johnson to split into two companies

The world's largest health-products company by sales revealed earlier today that it plans to split the consumer health division from the pharmaceuticals unit. After the split, the consumer health business will become a new publicly traded company.

Joaquin Duato, J&J's CEO starting January 2022, stated: "The new Johnson & Johnson and the New Consumer Health Company would each be able to more effectively allocate resources to deliver for patients and consumers, drive growth and unlock significant value."

Despite the split, the company plans to keep its total dividend "at least at the same level" – 2.6%.

The business separation is expected to be complete in 18 to 24 months. J&J will keep the pharmaceuticals and medical device units, expected to generate roughly $77 billion in revenue in 2021.

J&J is the second US company this week that announces a split, after General Electric. After the news hit the wires, Johnson & Johnson stock price added 4% before the opening bell.


This information prepared by is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.

This information is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation or the particular needs of any recipient.

You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.

This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent.

Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of